Pamela L. Kunz, M.D., has been appointed Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center and Director of GI Medical Oncology within the Section of Medical Oncology.\n Kunz joins Yale from Stanford University School of Medicine where she is currently Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Research Group, and Director of the Neuroendocrine Tumor Fellowship. “Beyond her record of accomplishment in GI Oncology, Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this difficult diagnosis,” said Charles Fuchs, M.D., M.P.H., director of Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital.\n Kunz serves on the Board of Directors for the North American Neuroendocrine Tumor Society, is Vice Chair of the National Cancer Institute Neuroendocrine Tumor Task Force. Previously, Kunz served as Chief Resident in Internal Medicine and completed a Clinical and Research Fellowship in Medical Oncology at Stanford University. She received her undergraduate and medical degrees from Dartmouth College and Dartmouth Medical School. “We look forward to working with Dr. Kunz and our entire Gastrointestinal Cancers Program to continue to expand the impact of our clinical, research, educational, and outreach initiatives in GI Cancers, including the expansion of a broad program in colorectal cancers,” said Roy S. Herbst, M.D., Ph.D., Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital and Associate Director for Translational Research. Kunz will start her new position in July.